Search Results - "Fontaine, Marilyn"
-
1
Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens
Published in Journal of clinical oncology (01-02-2023)“…TPS281 Background: CTX-009 is a recombinant bispecific antibody that binds both delta-like ligand-4 (DLL4) and vascular endothelial growth factor A (VEGF-A)…”
Get full text
Journal Article -
2
Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen
Published in Journal of clinical oncology (01-02-2023)“…TPS640 Background: CTX-009 is a recombinant bispecific antibody that binds both delta-like ligand-4 (DLL4) and vascular endothelial growth factor A (VEGF-A)…”
Get full text
Journal Article -
3
Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs)
Published in Journal of clinical oncology (20-05-2021)“…Abstract only 4147 Background: Retrospective studies of phosphorylated STAT3 (pSTAT3, a regulator of gene expression) in cancer-lineage cells have suggested it…”
Get full text
Journal Article -
4
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Published in Clinical cancer research (01-09-2022)“…To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or…”
Get full text
Journal Article -
5
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Published in Clinical colorectal cancer (01-03-2023)“…Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone…”
Get full text
Journal Article -
6
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
7
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma
Published in Clinical cancer research (26-05-2022)“…To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or…”
Get full text
Journal Article -
8
Breaking the silence
Published in Canadian dimension (01-03-1992)“…The issue of violence against aboriginal women and children was brought out by the Aboriginal Women's Unity Coalition. The Canadian group supported an…”
Get full text
Magazine Article